Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POTOMAC: Durvalumab + BCG in High-Risk, BCG-Naïve Non-Muscle Invasive Bladder Cancer
NCT03528694Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2018
- Primary completion
- Apr 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 12
01
Overview
A Phase 3 trial of durvalumab in non-muscle-invasive bladder cancer (NMIBC), sponsored by AstraZeneca. Started May 2018; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03528694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03528694.